✦ LIBER ✦

430 Dose finding of inecalcitol, a new VDR agonist, in combination with docetaxel–prednisone regimen for castrate-resistant prostate cancer (HRPC) patients (pts)

✍ Scribed by J. Medioni; G. Deplanque; J.M. Ferrero; T. Maurina; J.M. Rodier; E. Raymond; G. Allyon; S. Renaux; J.F. Dufour-Lamartinie; S. Oudard

Book ID: 119603113
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 47 KB
Volume: 8
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(10)72137-6

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

710 DOSE FINDING AND EFFICACY PHASE 2 ST

710 DOSE FINDING AND EFFICACY PHASE 2 STUDY OF INECALCITOL, A NEW VDR AGONIST, IN COMBINATION WITH DOCETAXEL-PREDNISONE REGIMEN FOR CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS (PTS)

✍ Medioni, Jacques; Deplanque, Gael; Maurina, Tristan; Ferrero, Jean-Marc; Rodier, 📂 Article 📅 2011 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 150 KB

7030 Dose finding and safety analysis of

7030 Dose finding and safety analysis of inecalcitol in combination with docetaxel-prednisone regimen in hormone-refractory prostate cancer (HRPC) patients (pts)

✍ Medioni, J.; Deplanque, G.; Maurina, T.; Ferrero, J.M.; Rodier, J.M.; Raymond, E 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 55 KB

POD-11.01: Dose Finding and Safety Analy

POD-11.01: Dose Finding and Safety Analysis of Inecalcitol in Combination with Docetaxel-Prednisone Regimen in Hormone-Refractory Prostate Cancer (HRPC) Patients (PTS)

✍ J. Medioni; G. Deplanque; T. Maurina; J. Ferrero; J. Rodier; E. Raymond; J. Ally 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 150 KB

Phase I Safety and Pharmacodynamic of In

Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients

✍ Medioni, J.; Deplanque, G.; Ferrero, J.-M.; Maurina, T.; Rodier, J.-M. P.; Raymo 📂 Article 📅 2014 🏛 American Association for Cancer Research 🌐 English ⚖ 360 KB

7024 Phase Ib dose-finding trial of intr

7024 Phase Ib dose-finding trial of intravenous (i.v.) panobinostat (PAN) with docetaxel (DOC) and prednisone (PRED) in patients (pts) with castration resistant prostate cancer (CRPC)

✍ Vaishampayan, U.; Rathkopf, D.; Chi, K.N.; Hotte, S.; Vogelzang, N.; Alumkal, J. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 66 KB